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As cancer cell genomes are unveiled at a breathtaking pace, the genetic principles at play in cancer
are emerging in all their complexity, prompting the assessment of classical genetic interaction
models. Here, we discuss the implications of these findings for cancer progression and heteroge-
neity and for the development of new therapeutic approaches.Over the past 30 years, intensive research has led to a reasonable
understanding of many cellular functions at the molecular level
and how these processes go awry in cancer. However, the
genetic principles that underlie the evolution of cancer genomes
and how combinations of mutations contribute to cancer pheno-
types remain poorly defined. These underlying principles are
likely to be similar to those governing genetic variation in healthy
cells and evolutionary processes in organisms, but this assump-
tion remains untested. Here, we discuss emerging ideas on the
genetic interactions in cancer and how they may be used to
design new therapeutic approaches.
Cancer Genes and Cancer Genomes
As a cell progresses from normal to cancerous, the biological
imperative to survive and perpetuate drives fundamental
changes in the cell’s behavior. These series of attributes, which
are most succinctly described as the ‘‘Hallmarks of Cancer’’
(Hanahan and Weinberg, 2000; Luo et al., 2009b; Hanahan and
Weinberg, 2011), are required for the development of amalignant
tumor. However, numerous questions remain about how muta-
tions in DNA lead to the acquisition of these traits. First, many
‘‘cancer genes’’ still await discovery, but even when these genes
are known, it is mostly unclear how they connect to transforma-
tive phenotypes. Moreover, for specific tumor phenotypes, it is
not yet known whether transformative mutations are selected
from a smorgasbord of functionally equivalent changes in
different genes. Or, is cancer progression an ordered procession
of mutation acquisition, with each mutation individually and
incrementally increasing tumorigenicity, and is the order of
acquisition itself important or is it simply the slate of genes that
is relevant?
Although the number of cancer genomes currently available
for scrutiny is relatively small, this is set to rise dramatically
over the next year. Nevertheless, it is already apparent that the
landscapes of cancer genomes can be incredibly complex.
Tumor cells may possess a panoply (104–105) of genetic
changes compared to germline DNA, which include highly
complex structural rearrangements in combination with base
changes, insertions and deletions (i.e., indels), and copy-number
changes (i.e., amplifications and deletions). These genetic30 Cell 145, April 1, 2011 ª2011 Elsevier Inc.changes likely arise from endogenous chemical reactions with
DNA and physiological processes, such as replication, but also
from the activity of exogenous mutagenic agents, such as ultra-
violet light, chemicals in tobacco smoke, and even chemo-
therapy. The differential activity of DNA repair processes may
considerably influence whether these insults become fixed as
heritable mutations. Theoretical considerations have led to the
suggestion that only a limited number of genetic alterations
(less than 10) may be absolutely required for tumor formation;
these are usually referred to as driver mutations. If this number
is reasonably accurate, it suggests that most of the genetic
change in a tumor cell is collateral damage due to either muta-
genic exposure and/or defects in DNA repair processes; these
changes are called passenger mutations.
Mutational changes in genes can be classified biologically by
their functional effect on the encoded protein. In cancer
research, a long-standing distinction is made between ‘‘onco-
genes’’ that incur dominant gain-of-function mutations (i.e.,
neomorphic mutations) and ‘‘tumor suppressor’’ genes that
develop recessive loss-of-function mutations (hypomorphic
mutations). Together these two types of mutations drive disease
progression. Mutations can also have dominant-negative
(antimorphic) effects; when only one allele is lost, this leads to
dosage-dependent haploinsufficiency (Santarosa and Ashworth,
2004), which has also been recognized as contributing to cancer.
A functional subdivision of tumor suppressors into caretaker,
gatekeeper, and landscaper genes has also been proposed
(Kinzler and Vogelstein, 1997; Michor et al., 2004). Caretaker
genes, when mutated, lead to genomic instability and enhanced
mutation acquisition. In contrast, gatekeeper genes encode
proteins that restrain cell growth, and disrupting their function
allows enhanced cell proliferation. Finally, defective landscaper
genes foster a microenvironment conducive to tumor cell
survival. Doubtless other categories of genes will also have
a significant role in cancer.
The Nature of Genetic Interactions in Cancer
Clearly, the complexity of cellular systems does not arise from
the independent action of a large number of different genes
but is rather the result of extensive genetic interactions among
Box 1. Glossary
This glossary presents the consensus definitions of terms used in the
text. Definitions of many terms vary, and many of the concepts and
terms overlap considerably in meaning.
Mutations and Alleles
d Driver mutation: Genetic alteration that provides an advantage to
cells facilitating tumor formation and survival. Driver mutations may
not necessarily be required at all points in the natural history of the
disease.
d Passenger mutation: Tumor-specific genetic alteration that is not
essential for tumor formation.
d Gain-of-function mutation: Mutation that increases a gene prod-
uct’s activity or results in a new function. Subclassifications include
hypermorphs, for which the mutation increases normal gene func-
tion; neomorphs, for which the dominant gain of function is distinct
from normal function; and antimorphs, for which the dominant
mutations act to oppose normal gene function.
d Loss-of-function mutation: Mutation that decreases or destroys
the gene product’s function. Subclassifications include amorphs,
where the mutation completely ablates normal function (also known
as a null mutation); and hypomorphs, where the mutation partially
disrupts normal function.
d Haploinsufficiency: An allele dosage effect in which diploid cells
carry a single active copy of a particular gene and that copy is
insufficient to support the function of two wild-type alleles.
d Caretaker, gatekeeper, and landscaper genes: A classification of
genes involved in cancer. Caretaker genes encode products that
engage in maintaining the stability of the genome, such as the genes
involved in DNA repair. Gatekeeper genes encode proteins that
restrain cell growth, and their loss of function allows enhanced cell
proliferation and the transmission of mutations. Landscaper genes
encode products that, when mutated, contribute to the abnormal,
neoplastic growth of cells by fostering a microenvironment condu-
cive to unregulated cell proliferation.
d Gradualism: The gradual and stepwise accumulation of tumorigenic
mutations over time.
d Chromothripsis: The nearly simultaneous acquisition of multiple
mutations in a tumor cell via the catastrophic shattering and then
reassembly of chromosomes.
Gene Interactions
d Epistasis or gene interaction: When the effects of one gene are
modified by one or several other genes, which are often called
modifier genes. In contrast to dominant/recessive effects that
describe the interaction between alleles of the same gene, epistatic
effects describe the interaction between genes at different loci.
When the phenotype of multiple genes is expressed within the
context of a gene interaction, these genes are defined as epistatic;
when the genes’ phenotype is repressed within the context of the
gene interaction, these mutations are defined as hypostatic. In
functional terms, these gene interactions can also be defined as
genetic suppression or enhancement effects; that is, the combina-
tion of gene effects on a phenotype is less or more profound than the
expected combination of single-gene effects, respectively.
d Synthetic lethality: A gene interaction in which single-gene defects
are compatible with cell viability, but the combination of gene effects
results in cell death (Figure 1). The term synthetic lethality is from the
Greek, syndyάzu or ‘‘syndiazo,’’ which means ‘‘two or more features
combined.’’
d Synthetic sickness: A gene interaction in which a combination of
changes in different genes generates a greater deleterious effect
on the fitness of a cell than would be expected given the individual
phenotypes of individual mutations (Figure 1B).
Box 1. Continued
d Synthetic viability: The reverse of synthetic lethality. One gene
alteration causes lethality, but in the presence of a second alteration
in another gene, the cell is viable (Figure 1).
d Hard and soft synthetic lethalities: Describes the extent to which
synthetic lethal interactions between two genes are modulated by
changes in additional genes. Hard synthetic lethalities are relatively
unaffected by changes in additional genes, whereas soft synthetic
lethalities can be readily rescued by alterations in other genes.
Ideally, the preferred targets of cancer therapy are hard synthetic
lethalities.
d Non-cell-autonomous synthetic lethality: Synthetic lethality that
occurs between two or more genes in different cells.
d Functional buffering: The ability of complex molecular systems to
buffer against the tendency of new alleles to impair cell fitness or
viability. This term is also known as genetic canalization.
d Gene addiction: The ability of a cell to become completely depen-
dent upon the activity of a gene. In cancer, tumor cells often become
addicted to the activity of oncogenes. A prime example of gene
addiction is the dependency of chronic myelogenous leukemia cells
on the constitutive activity of ABL kinase.
d Functional redundancy: When two or more genes, proteins, or
pathways perform similar, interchangeable activities. Synthetic
lethality can occur between genes with functional redundancy.
d Induced essentiality: A refined model of the synthetic lethality
concept; when the functional buffering that occurs in response to
a cancer gene mutation results in a dependency or addiction to
another gene.
d Genetic capacitor: A protein or molecular system that restricts the
ability of genetic variation to change phenotype. Heat shock proteins
are regarded as an example of a genetic capacitor because they
restrict the deleterious effects of a highly mutated cancer proteome.
d Network compatibility: When the acquisition of successive muta-
tions in the natural history of a tumor is defined by their compatibility
with pre-existing mutations and the functional buffering that has
occurred alongside existing mutations.them. Although definitions for ‘‘genetic interactions’’ vary, they
can often be described as epistasis and then further subclassi-
fied as either enhancement or suppressive effects. For example,
considering the effect of mutating two genes, A and B, on
a phenotype such as cell fitness (Figure 1), these genes have
an enhancement interaction when a combination of mutations
in both genes has a far greater effect on cell fitness than would
be predicted by a simple combination of individual gene effects.
Conversely, a genetic suppression interaction produces a less
profound effect when both genes are mutated than would be ex-
pected from the combination of individual gene effects. These
gene interactions can be extreme and result in cell death or at
least a significant reduction in the fitness of cells. For example,
synthetic lethality and synthetic sickness (Dobzhansky, 1946;
Lucchesi, 1968) describe the scenario where single-gene
defects are compatible with cell viability but the synthesis or
combination of gene effects results in cell death or a significant
impairment of fitness. At the other extreme is a combination of
gene effects that rescues the lethal effects of a single gene
change; we term this effect synthetic viability, given its inverse
relationship to synthetic lethality.
So how do such concepts impact upon our understanding of
the genetic interactions in cancer? Cooperative interactionsCell 145, April 1, 2011 ª2011 Elsevier Inc. 31
Figure 1. Gene Interactions in Cancer
(A) Extreme forms of genetic interaction are defined by synthetic lethality
(in which a combination or synthesis of gene mutations causes cell death) and
the reverse scenario, synthetic viability (in which a combination of gene effects
rescues the lethal effects of a single gene change).
(B) Different modes of genetic interaction defined by quantitative effects on
a phenotype, such as cell fitness. Here the value 1 represents the maximal
fitness of cells, and the individual effects of changes in genes A (0.7) or B (0.5)
are shown. When no interaction between genes A and B exists, the simple
combination of effects (shown here as 0.7 3 0.5 = 0.35) is expected; any
deviation from this value suggests an interaction between genes A and B.between oncogenes, such as the transcription factor gene
MYC and the GTPase gene RAS, have long been recognized
as contributing to the processes of transformation and
immortalization (Land et al., 1983). This type of interaction was
originally viewed as a genetic enhancement effect. However,
and perhaps counterintuitively, some cancer drivers, such as
activated mutant RAS, while imparting a selective advantage
to tumor cells can also cause deleterious effects, and gene
interactions can act to mitigate these. RAS activation causes32 Cell 145, April 1, 2011 ª2011 Elsevier Inc.oncogene-induced senescence, a process driven by the exces-
sive firing of multiple replication forks, the activation of ATM, and
a DNA damage response (Bartkova et al., 2006; Di Micco et al.,
2006). Inactivation of ATM suppresses the effect of RAS on
oncogene-induced senescence and therefore represents an
example of synthetic viability.
Similarly, loss of either BRCA1 or BRCA2 tumor suppressor
gene function in cells triggers a cell-cycle arrest at the G2/M
checkpoint that can be suppressed by the inactivation of P53
(Connor et al., 1997; Liu et al., 2007). This situation may also be
viewed as a relationship between gatekeeper and caretaker
mutations, in which caretakers such as BRCA1 and BRCA2
protect the genome against the potentially mutagenic and
tumorigenic effects of DNA damage, whereas gatekeepers
such as P53 induce cell death or cell-cycle arrest of cells that
have lost caretaker function. Similarly, loss of VHL (Von Hippel-
Lindau tumor suppressor) function normally causes cellular
senescence, but inactivation of a second tumor suppressor, RB
(Retinoblastoma), can suppress this process (Young et al., 2008).
As a final example of genetic suppression, the reliance ofmany
tumor cells on molecular chaperones, such as HSP90, may be
viewed as reflective of an entire series of gene interaction effects.
Molecular chaperones facilitate protein folding and aggregation
in normal cells, and in tumor cells HSP90 probably suppresses
some of the deleterious effects of a highly mutated proteome,
acting as a form of genetic capacitor (Whitesell and Lindquist,
2005).
The simple gene interactions described above almost
certainly reflect the nature of biological systems: complex
networks of interactions that maintain cellular homeostasis,
fitness, and survival in the face of environmental and/or genetic
change. In essence, these gene interactions provide functional
buffering (Hartman et al., 2001), sometimes described as genetic
canalization—that is, the buffering of pathways against the
tendency of new alleles tomake nonoptimal phenotypes (Gibson
andWagner, 2000;Waddington, 1959). For example, loss of cell-
cycle checkpoints functionally buffers and reduces the delete-
rious effects of BRCA dysfunction or VHL loss, allowing the
cell to survive, albeit with a modified phenotype.
Large-scale mutagenesis studies in worms and yeast suggest
that these functional buffering networks are relatively pervasive.
Most single-gene deletion mutations do not impair viability or
fitness, at least under laboratory conditions. This suggests that
either themajority of genes are not involved inmaintaining cellular
viability or cell division or, perhaps more likely, functional buff-
ering against the dysfunction of an individual gene is common
(Giaever et al., 2002; Kamath et al., 2003). Supporting this latter
hypothesis, analysis of viable yeast strains with deletion muta-
tions indicates that nearly all mutants display perturbed gene
expression profiles. This suggests that the loss of almost any
nonessential gene may result in a compensatory change in the
molecular network (Hugheset al., 2000).Clearly, this is potentially
bad news for cancer therapies that aim to block individual path-
ways. However, systematic functional screens in model organ-
isms have also shown that each nonessential gene typically has
between 10 and 30 synthetic lethal partners (Baryshnikova
et al., 2010), suggesting that intervening at a ‘‘sweet spot’’ might
overcome compensatory network rearrangements.
Concepts of gene interaction and functional buffering are crit-
ical for understanding tumor evolution. Most existing models of
cancer progression have assumed that in the majority of cases,
the acquisition of cancer-promoting mutations occurs cumula-
tively, perhaps over years to decades (Jones et al., 2008).
However, mutagenic ‘‘big bangs,’’ such as those driven by telo-
mere attrition (O’Hagan et al., 2002), or chromothripsis (the
shattering and then reassembly of chromosomes) (Stephens
et al., 2011) challenge the universality of this gradualism dogma.
Regardless of the mechanism, it seems reasonable to assume
that cancer progression is partly shaped in some form by both
synthetic lethal and synthetic effects. For example, given that
BRCA dysfunction induces an acute cell-cycle arrest in the pres-
ence of functional P53, it seems reasonable to propose that P53
dysfunction usually precedes BRCA loss of function, generating
a permissive state and synthetic viability.
In the example above the order in which mutations occur is
likely defined by the genetic interactions involved. In other situa-
tions it may be that the nature of the genes mutated is more
important than the order (Anderson et al., 2011). Currently, it is
unknown which situation is the more prevalent phenomenon,
which is due in large part to the paucity of studies examining
the order in which oncogenic driver mutations accumulate
from an original clonal population. Nevertheless, some general
principles may be emerging.
First, for the cell to remain viable when two mutations occur
successively in a cell, the second mutation must be compatible
with the effect of the first mutation. Moreover, the second
mutation must also be compatible with any functional buffering
mechanism that mitigates the deleterious effects of the first
mutation. In addition, driver mutations cannot be synthetically
lethal with mutations that occur earlier in the ultimate tumor
cell lineage. Most mutations in the natural history of a tumor
that result in a phenotype may need to fit into this schema of
network compatibility. If this is the case, it could result in genetic
canalization. For example, in the face of tumor-associated muta-
tions and the network remodeling that mitigates the potentially
deleterious effects of mutation, the spectrum of subsequent
mutations that are compatible with these changes could be
restrictive. This could ultimately cause an evolutionary progres-
sion that is increasingly stereotyped. Moreover, this genetic
ratcheting may partially explain the relatively nonrandom histo-
logical features of tumor types. It may also explain the recurrence
of specific mutations in particular types of tumor; in some cases
once an initial driver mutation is in place, the eventual fate of any
surviving daughter cell is essentially sealed, or at least partially
defined.
Heterogeneity in Cancer: Context Dependence
of the Phenotypic Effects of Mutations
Multiple mechanisms have been proposed to explain the pheno-
typic heterogeneity of cancer, including differences in the cells of
origin, heterotypic interactions between cancer cells and their
microenvironment, and the plasticity of so-called cancer ‘‘stem
cells’’ (i.e., cells that have an indefinite potential for self-renewal
and that drive tumorigenesis) (Vargo-Gogola and Rosen, 2007;
Visvader, 2011). In addition, the interplay among the functional
consequences of genetic and heritable epigenetic aberrations,synthetic lethal and viable interactions, and genetic canalization
likely play major roles in generating the diversity of cancer
phenotypes.
The availability of cancer genomes at base-pair resolution is
allowing a detailed analysis of the relationships between cancer
genotypes and phenotypes (Figure 2). In particular, the genomes
of ‘‘rare’’ types of cancers are providing useful information. Rare
types of cancer, which often have specific histological appear-
ance, may be driven by pathognomonic genetic aberrations
(i.e., ones that are distinctively characteristic of a particular
disease) (Figure 2C). An example of this comes from sequencing
studies in two rare and histologically distinct types of ovarian
cancer, granulosa cell tumors and clear cell carcinomas. Muta-
tions in the transcription factor FOXL2 (Shah et al., 2009a) are
common in granulosa cell tumors, whereas ovarian clear cell
carcinomas have recurrent genetic changes affecting a few
driver genes, particularly ARID1A (AT Rich-interactive domain
1A [SWI-like]) and PPP2R1A (Protein Phosphatase, Subunit A,
R1-alpha isoform) (Jones et al., 2010; Wiegand et al., 2010).
Some rare cancer types also have similar phenotypes and driver
events but can occur in different anatomic sites. For example,
adenoid cystic carcinomas of both breast and salivary glands
are characterized by almost identical histological features, and
both tumors carry the oncogenic MYB-NFIB fusion gene (Pers-
son et al., 2009) (Figure 2A). These examples suggest that
sequencing the phenotypic extremes represented by the
‘‘rare’’ cancer types may constitute a way to reduce the hetero-
geneity of cancers a priori and thus facilitate the identification of
recurrent driver mutations.
Adding an increasing level of complexity to our understanding
of genotype-phenotype relationships in cancer, a number of
tumors are now known to share identical driver mutations even
though the tumors arise in distinct anatomical sites and exhibit
different histological features and clinical behavior. These obser-
vations suggest that some mutations may generate divergent
phenotypes in different environments and cell types
(Figure 2B). Activating KIT (v-kit Hardy-Zuckerman 4 feline
sarcoma viral oncogene homolog) mutations drive not only
gastrointestinal stromal tumors but also mucosal and acral
(i.e., palmoplantar and subungual) melanomas and mast cell
disorders (Davies et al., 2006; Davies and Samuels, 2010). In
addition, the ETV6-NTRK3 (ETS variant 6-neurotrophic tyrosine
kinase, receptor, type 3) fusion gene can drive tumors from
distinct anatomical sites, with different differentiation lineages
and dissimilar clinical behaviors (Lannon and Sorensen, 2005).
Although it is not completely clear why this occurs, the interplay
between cell of origin and the specific mutation undoubtedly
provides some explanation for convergent and divergent pheno-
types (Figures 2A and 2B). One possible mechanism underlying
this phenomenon might be that a driver mutation has an overt
impact on the ability of cells to differentiate, so that these aber-
rations cause convergence toward the same phenotype regard-
less of the cell of origin. Nevertheless, in other cases, the cell
origin does influence the phenotype. For example, mutations in
Ctnnb1 (b-catenin) have little impact on progenitor cell popula-
tions in the cerebellum, but they may drive medulloblastoma
development when present in embryonic dorsal brainstem cells
(Gibson et al., 2010).Cell 145, April 1, 2011 ª2011 Elsevier Inc. 33
Figure 2. Genotypic-Phenotypic Correlations in Cancer
(A) Convergent phenotypes: tumors of similar, if not identical, phenotypesmay
be driven by distinct genetic aberrations. Convergent phenotypes are,
perhaps, best exemplified by gastrointestinal stromal tumors, which have
remarkably similar histological characteristics and clinical behavior but are
driven by mutations in either KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog) or PDGFRA (platelet-derived growth factor receptor,
peptide A), or more rarely by mutations in SDHB (succinate dehydrogenase
complex, subunit B, iron sulfur [Ip]) or SDHC (succinate dehydrogenase
complex, subunit C, integral membrane protein, 15 kDa) (Janeway et al., 2011).
In addition, mouse models have demonstrated that inactivation of Brca1 and
Tp53 in lumenal progenitor and basal cells of the mouse mammary gland lead
to the development of tumors with similar histological features, immunohis-
tochemical characteristics, and transcriptomic profiles (Liu et al., 2007;
Molyneux et al., 2010).
(B) Divergent phenotypes: tumors of distinct phenotypes (originating either
in the same cell or from cells of different cell lineage) and having distinct
clinical behaviors may possess identical driver genetic aberrations. For
example, subgroups of gastrointestinal stromal tumors, mucosal and acral
melanomas, as well as mast cell disorders are all driven by activating KIT
mutations. Likewise, the oncogenic ETV6-NTRK3 (ETS variant 6-neurotrophic
tyrosine kinase, receptor, type 3) fusion gene is one of the defining features of
congenital fibrosarcomas, cellular mesoblastic nephromas, secretory carci-
nomas of the breast, acute myeloid leukemias, tumors from distinct anatom-
ical sites, distinct differentiation lineages, and different clinical behaviors
(Lannon and Sorensen, 2005).
(C) Correlations between prevalence, phenotypic diversity, and genetic
heterogeneity of epithelial malignancies. Common epithelial malignancies are
phenotypically diverse, given that they comprise operational subgroups of
multiple diseases and are not discrete biological entities. These cancers are
often genetically unstable they often harbor a multitude of mutations that are
usually private (i.e., unique to an individual cancer) and that may affect several
molecular pathways. Tumors with phenotypes that are relatively homoge-
34 Cell 145, April 1, 2011 ª2011 Elsevier Inc.In addition to the genetic heterogeneity between cancers,
strong evidence now indicates that genetic heterogeneity also
occurs within individual tumors (Anderson et al., 2011; Ding
et al., 2010; Mullighan et al., 2008; Shah et al., 2009b). A substan-
tial proportion of cancers may be composed of a mosaic of
nonmodal populations of cells (i.e., populations that account
for <50% of all cancer cells) that, although they share the same
initiatingevent, evolve through theacquisitionofadditionalgenetic
aberrations. This evolution may explain not only the phenotypic
diversity within a given cancer (Geyer et al., 2010) but also the
cancer’s proclivity to metastasize to distinct anatomical sites
(Ding et al., 2010; Shah et al., 2009b) as well as its resistance to
both chemotherapy and targeted therapies (Mullighan et al.,
2008).
Genetic differences between primary tumor and metastatic
deposits and the existence of genetic heterogeneity with a tumor
raise some interesting questions about the universal importance
of the phenomenon of tumor self-seeding by circulating cancer
cells (Kim et al., 2009) and ‘‘cancer stem cells’’ (Anderson
et al., 2011). The phenotypic diversity within cancers has been
ascribed to the existence of cancer stem cells and their ability
to differentiate down multiple lineages (Reya et al., 2001).
However, in one study, sorted populations of both putative
cancer stem cells and more differentiated cells displayed similar
genetic heterogeneity found in the bulk of the tumor (Anderson
et al., 2011). Moreover, at least in some cases, phenotypically
distinct areas within a given tumor are underpinned by distinct
patterns of genetic alterations (Geyer et al., 2010). Finally,
leukemias that were genetically heterogeneous at the time of
diagnosis maintain this genetic heterogeneity upon serial trans-
plantation (Anderson et al., 2011). These results do not neces-
sarily refute the case for cancer stem cells, but at least in these
situations, a Darwinian or clonal cancer evolution mechanism
for cancer heterogeneity appears much more likely.
Deep sequencing of cancer metastases indicates that, as with
primary cancers, metastases may be composed of multiple
clones that have acquired genetic abnormalities not detectable
in the primary tumor (Anderson et al., 2011; Ding et al., 2010;
Mullighan et al., 2008; Shah et al., 2009b). Independent studies
of leukemias have now demonstrated that the clones harboring
the most complex patterns of genetic aberrations are not neces-
sarily the dominant clones or the clones that will be the source of
relapse after therapy (Anderson et al., 2011; Mullighan et al.,
2008). In fact, instead of outright competition or predatory inter-
actions, a more complex interplay between genetically distinct
populations within a cancer may take place (Marusyk and
Polyak, 2010). Examples have been documented of both
commensalism, or a positive interaction in which one clone
benefits the other without itself being affected, and mutualism,
or cooperation between cancer cell populations (Calbo et al.,neous usually have low-to-moderate levels of genetic instability and are driven
by a limited repertoire of genetic aberrations, which are relatively recurrent.
Rare cancer types are phenotypically homogeneous and are often driven by
pathognomonic genetic aberrations. Not all rare cancer types have low levels
of genetic instability, but even when they are more genetically unstable, the
repertoire of genetic aberrations found in rare and phenotypically homoge-
neous cancers appears to be more limited than that found in common cancer
types.
Figure 3. Therapeutic Implications of Gene
Interactions
(A) Classical synthetic lethality and induced essenti-
ality (Tischler et al., 2008). Classically, synthetic lethal
relationships (shown here between gene A and gene
B) have generally been discussed in terms of func-
tional redundancy between genes or proteins that
have similar functions (top). This model describes
systems where A and B are relatively interchangeable
in terms of function. Although this model likely applies
to some forms of synthetic lethality, the revised model
of induced essentiality is particularly pertinent to
cancer (bottom). This model relies upon the inherent
plasticity of biological networks and their ability to
respond to perturbation. Here, loss of gene A is
compatible with viability but only because molecular
networks reorder to accommodate this perturbation.
In this new state, gene B is now essential, and its
inhibition causes cell death (i.e., synthetically lethal
with gene A).
(B) Some lethal genetic interactions likely occur
because of the interaction of genes only within one
cell (i.e., cell-autonomous synthetic lethality) (top).
However, gene interactions between different cells
can also cause lethality (bottom). This could be in cells
that directly interact with the tumor cells (e.g., fibro-
blasts) or distant cells producing growth-promoting
hormones such as estrogen.2011). These phenomena may be related to the high prevalence
of genetic heterogeneity within cancers and the observation that,
at early and late stages of disease evolution, there may be no
absolute dominance of a single clone (Marusyk and Polyak,
2010).
The impact of intratumor heterogeneity on the metastatic
ability of a given cancer has been the subject of considerable
discussion (Klein, 2009). Data from gene expression profiling
studies led to the suggestion that the metastatic behavior of
a cancer was determined at an early stage and that all cells within
a given cancer would have a similar proclivity to give rise to
metastases (Weigelt et al., 2003). Recent sequencing studies
have called into question these concepts. In pancreatic cancers,
metastatic clones may harbor specific genetic aberrations, and
the acquisition of metastatic ability occurs at a later stage. There
is evidence to suggest that it may take at least 5 years for a fully
malignant but nonmetastatic clone to transform into ametastatic
‘‘founder’’ clone (Yachida et al., 2010). On the other hand, clinical
observations suggest that the existence of clones fully capable
of metastatic dissemination may be present at the early stage
of the development of some types of cancer, such as ‘‘triple-
negative’’ breast cancers (Foulkes et al., 2010). It seems likely
that in different cancer types, the timing differs for the emergence
of a clone fully capable of metastatic dissemination. Moreover,
this timing may depend on the size of the cancer cell pool, the
levels of genetic instability, intratumor genetic heterogeneity,
and proliferation rates of cancer cells (Foulkes et al., 2010).
Therapeutic Implications
Although some of the concepts we present in this Perspective
could be viewed as semantic or even speculative, we believe
they may have considerable utility in the development of newtherapeutic approaches for cancer. Over the past few years,
rapid and significant advances have been made in directly tar-
geting the dependency or addictions that some tumor cells
have on gain-of-function oncogenic mutations, such as the
BCR-ABL fusion gene, the ERBB2 amplification, and the BRAF
V600E mutation (reviewed by Lord and Ashworth, 2010 and
Haber, this issue). Conversely, little progress has been made in
targeting tumor suppressor gene dysfunction, despite the rela-
tively long-standing ability to identify and characterize these
genes. However, by applying synthetic lethal concepts, this is
nowpossible. The first example, at least knowingly, of a synthetic
lethal therapy to reach the clinic is the targeting of BRCA1- or
BRCA2-deficient tumor cells with PARP (poly(ADP-ribose)
polymerase) inhibitors, and this potential success story estab-
lishes a new paradigm for drug development (Ashworth, 2008).
In essence, the relationship between BRCA and PARP is a true
synthetic lethal one; normally PARP activity is not essential, but
in the absence of BRCA gene function, PARP activity is critical
for cell survival. Rather than representing a strict functional
redundancy between BRCA and PARP, this effect is more likely
to be an induced essentiality effect (Tischler et al., 2008)
(Figure 3A) and a form of functional buffering. In clinical trials,
PARP inhibitors can elicit significant and sustained antitumor
responses in patients with BRCA1 or -2mutant tumors that arise
at different sites, such as breast, ovary, and prostate (Fong et al.,
2009). Likewise, in vitro BRCA-deficient cells, even those with
experimentally imposed BRCA dysfunction, are profoundly
sensitive to PARP inhibitors, almost regardless of the histology
or genetic background involved. The BRCA-PARP synthetic
lethality also appears relatively unaffected by potential compen-
satory changes in the cell. This may be because there are few
buffering mechanisms for this particular gene interaction, andCell 145, April 1, 2011 ª2011 Elsevier Inc. 35
this interaction thus constitutes what we term a hard synthetic
lethality.
From a network perspective, BRCA-PARP gene interaction
may be part of a relatively small network with few synthetic
viability interactions that can rescue the BRCA-PARP synthetic
lethality. Regardless of whether this is the case, one mechanism
of resistance to PARP inhibitors in cells with BRCA2 mutations
are secondary mutations that reinstate a functional BRCA2
isoform, resulting in one of the first examples of synthetic lethal
resistance (Edwards et al., 2008). If this mechanism turns out
to be pervasive, then it supports the hypothesis that few
synthetic viability interactions exist that can rescue PARP inhib-
itor resistance.
In contrast to the hard synthetic lethality observed between
BRCA and PARP, some of the recently identified gene interac-
tions involving RAS, although still de facto synthetic lethalities,
seem more susceptible to changes in cell type, context, and/or
genetic background (Barbie et al., 2009; Luo et al., 2009a; Scholl
et al., 2009); this effect we term soft synthetic lethality. This indi-
cates that the resilience of any synthetic lethal or gene addiction
effect must be stringently addressed on multiple genetic back-
grounds before consideration as a therapeutic approach. Exper-
imentally, these areas are now relatively straightforward to
address. With improvements in genetic screening approaches,
such as RNA interference, it is now feasible to systematically
identify synthetic lethal interactions and test how influenced
these are by compensatory network modifications (Ashworth
and Bernards, 2010).
Cancer therapy applies a highly stringent form of selective
pressure upon the tumor cell; the molecular mechanisms that
functionally buffer the inhibition of a cancer drug target and
that cause synthetic viability are most likely selected for and
have the potential to lead to therapy resistance. This is perhaps
most obviously seen in the numerous reports that describe resis-
tance to signal transduction kinase inhibitors that target the
mitogenic, prosurvival, and antiapoptotic functions of onco-
genes like BRAF (Johannessen et al., 2010; Nazarian et al.,
2010; Villanueva et al., 2010). After a strong initial response,
the therapeutic effect of BRAF inhibitors appears abrogated by
compensatory changes in the activity of other signaling path-
ways. From a genetics perspective, this could be seen as
synthetic viability between the drug target and the gene(s) that
leads to the compensatory mechanism. Hopefully, targeting
these compensatory mechanisms and the use of combinatorial
therapies, which simultaneously hit the primary target and the
likely buffering and resistance mechanisms, will prove useful.
Regardless of whether this turns out to be the case, clearly it is
not sufficient only to identify cancer drug targets that are tumor
selective; these targets must also be robust in the face of genetic
interactions and network compensation. Such networks of
genetic interactions are being comprehensively catalogued in
model organisms for which technical methods and many math-
ematical and computational approaches are already estab-
lished. It is debatable whether a significant number of these
gene interaction effects directly translate across species. There-
fore, identifying global networks in human cells, although techni-
cally challenging, is a major objective and potential outcome
from the burgeoning field of systems or network biology.36 Cell 145, April 1, 2011 ª2011 Elsevier Inc.Given the growing understanding of the interplay between
tumor cells and their microenvironment, and also between
individual tumor cells themselves (e.g., commensalism and
mutualism), it may be possible to exploit gene interactions that
occur between cells rather than within individual cells as a thera-
peutic approach. For example, a drug could induce changes in
the microenvironment or even macroenvironment that are
synthetically lethal with a mutation or gene addiction in a tumor
cell. Such non-cell-autonomous synthetic lethality (Figure 3B)
could already be represented by the interaction between
CYP19A1 (the gene-encoding aromatase) and genes encoding
estrogen receptors, like ESR1. Aromatase inhibitors, such as
anastrozole and letrozole, inhibit the production of estrogens by
targeting aromatase; this inhibition of hormone production
targets the genetic dependency of some breast tumor cells
upon ESR1 and estrogen signaling (Johnston and Dowsett,
2003). The identification of additional heterotypic cell-cell inter-
action networks will require the development of appropriate
in vitro or in vivo screening methodologies that better reflect the
biology of cancer.
Here, we have tried to make the case that viewing cancer
through the prism of genetic interactions may help us better
understand cancer biology and the development of new thera-
peutic approaches. However, it is important to emphasize that
these concepts by themselves merely generate hypotheses,
and their practical application will require a thorough under-
standing of the molecular mechanisms involved.ACKNOWLEDGMENTS
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